Breaking News
Upgrade 0
🇺 🚀 5 new AI-picked strategies for US stocks beating the market in healthcare, energy & more
Learn more
Close

Zhejiang Jingxin Pharmaceutical Co Ltd (002020)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
18.63 +0.22    +1.20%
07:22:42 - Delayed Data. Currency in CNY
Type:  Equity
Market:  China
ISIN:  CNE000001K73 
  • Volume: 13,846,383
  • Bid/Ask: 18.63 / 18.64
  • Day's Range: 18.50 - 19.30
Jingxin Pharm A 18.63 +0.22 +1.20%

Zhejiang Jingxin Pharmaceutical Co Ltd Company Profile

 
Get an in-depth profile of Zhejiang Jingxin Pharmaceutical Co Ltd, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

3909

Equity Type

ORD

Zhejiang Jingxin Pharmaceutical Co., Ltd. researches and develops, produces, and sells pharmaceutical products and medical devices in China and internationally. The company offers antihypertensive, antibiotics, quinolones, gastrointestinal promotion, antidiabetic, antiepileptic, antihistamine, H+ pump depressant, antihyper cholesterolemia, histamine H2 receptor blockader, antihyper cholesterolemirs, antidepressant, cephalosporin, and biopharma products; and API products, including ciprofloxacin, ciprofloxacin hydrochloride, ciprofloxacin lactate, levofloxacin hemihydrate, levofloxacin hydrochloride, levofloxacin lactate, enrofloxacin, enrofloxacin hydrochloride, simvastatin, rosuvastatin calcium, pitavastatin calcium, ticagrelor, rivaroxaban, apixaban, cisapride, levetiracetam, brivaracetam, sertraline HCI, rivastigmine bitartrate, pramipexole dihydrochloride, memantine hydrochloride, empagliflozin, dapagliflozin, marbofloxacin, and moxifloxacin. It also provides intermediates; and medical display products, such as diagnostic medical displays, surgical medical displays, clinical medical displays, medical large screens, medical integrated machines, ultrasonic medical displays, and other products. The company was formerly known as Zhejiang Jingxin Pharmaceutical Factory and changed its name to Zhejiang Jingxin Pharmaceutical Co., Ltd. in 2000. The company was founded in 1990 and is headquartered in Xinchang, China.

Contact Information

Address No. 800, Xinchang Avenue East Road Yulin Street
Xinchang, 312500
China
Phone 86 575 8617 6531
Fax 86 575 8609 6898

Top Executives

Name Age Since Title
Tianqing Hu 59 - Chairman of the Supervisory Board
Hu Wan 49 2022 Non-Independent Director
Zhang Daliang 60 2022 Independent Director
Lei Ying - 2022 Independent Director
Pan Xu 38 2022 Independent Director
Lv Gang 63 2013 President & Chairman of the Board
Wang Nengneng 52 2013 Vice Chairman
Jin Zhiping 44 2013 VP & Director
Chen Meili 55 2013 VP, CFO & Director
Yunfei Hong 45 2019 Secretary of the Board & Non-Independent Director
Jiaqi Lv - 2025 Non-Independent Director
Tao Huang - 2025 Independent Director
Fen Juan Lin 45 - Employee Representative Member of the Supervisory Board
Xiao Jun Xu 52 2019 Supervisor
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

002020 Comments

Write your thoughts about Zhejiang Jingxin Pharmaceutical Co Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email